Dasatinib + quercetin has stronger human evidence for senolytic activity than any natural alternative. Fisetin and quercetin alone have stronger evidence than many early-stage pharmaceuticals. The choice depends on: age, disease burden, access, risk tolerance, and cost. Most practitioners recommend starting with natural senolytics in one's 40s–50s and considering D+Q consultation from one's 60s onwards.

Can natural senolytics completely replace D+Q?

They cannot replicate D+Q's specific kinase inhibition mechanism or its evidence base. However, for individuals unwilling or unable to access dasatinib, fisetin + quercetin represent a meaningful and evidence-supported alternative.

At what age should I switch to D+Q?

There is no strict age threshold. Consider D+Q when: natural senolytic protocols show diminishing symptom improvement, age-related functional decline is accelerating, or when a longevity physician recommends it based on biomarkers and health history.